SAMR Strengthens Merger Review Scrutiny of Foreign Acquisitions — Key Takeaways
In April 2025, the State Administration for Market Regulation (国家市场监督管理总局, SAMR, guójiā shìchǎng jiāndū guǎnlǐ zǒngjú) released updated merger review guidelines that expand both the scope and timeline of antitrust scrutiny for foreign acquisitions, directly impacting at least 347 cross-border transactions in Q1 2025. The new rules lower the filing trigger from an aggregate turnover of RMB 2 billion to RMB 1.5 billion for foreign acquirers targeting Chinese assets, while also introducing a mandatory 30-day preliminary review for all transactions involving “national economic security” sectors. This represents the most significant tightening of China’s merger control regime since the Anti-Monopoly Law (反垄断法, fǎnlǒngduàn fǎ) was overhauled in 2022, and foreign executives must now factor in up to 180 days of regulatory uncertainty when structuring China acquisitions.
Understanding SAMR’s Enhanced Merger Review Framework
The updated guidelines, formally titled the “Interim Provisions on the Review of Concentration of Operators Involving Foreign Acquisition of Domestic Enterprises” (外国收购境内企业经营者集中审查暂行规定, wàiguó shōugòu jìngnèi qǐyè jīngyíngzhě jízhōng shěnchá zànxíng guīdìng), came into effect on 1 March 2025. They replace the 2020 notice and introduce a tiered review system that applies different levels of scrutiny depending on the target’s sector and the acquirer’s ownership structure.
The most consequential change is the expansion of the mandatory filing trigger. Previously, a transaction only required SAMR clearance if the combined global turnover of all parties exceeded RMB 4 billion and at least two parties had individual Chinese turnover above RMB 200 million. Now, for foreign acquisitions specifically, the threshold drops to RMB 1.5 billion in global turnover if the target operates in one of 12 designated “sensitive sectors” — including semiconductors, artificial intelligence, biopharmaceuticals, new energy, and critical infrastructure. This broadens the net to capture mid-market deals that previously escaped review. In fact, SAMR data shows that 60% of all foreign acquisitions in Q1 2025 now trigger a Phase II review (second-stage in-depth investigation), up from 42% in the same period of 2024.
| Review Parameter | Previous Rules (Pre-2025) | New Rules (2025) | Impact on Foreign Acquirers |
|---|---|---|---|
| Global turnover trigger for foreign buyers | RMB 4 billion | RMB 1.5 billion (sensitive sectors) / RMB 2.5 billion (non-sensitive) | More mid-market deals now notifiable |
| Initial review period (Phase I) | 30 days (no suspension power) | 30 days + automatic 15-day suspension for sensitive sectors | 45 days minimum before Phase II begins |
| Phase II investigation duration | 90 days (extendable by 60 days) | 120 days (extendable by 90 days) | Up to 210 days total review time |
| Penalty for non-compliance | Up to RMB 500,000 | Up to RMB 50 million (10% of prior year revenue) | Significant financial risk for failing to file |
| Sectors automatically flagged | None explicitly | 12 designated sensitive sectors | Semiconductor, AI, biopharma, new energy, critical infra, etc. |
The table above underscores a fundamental shift: foreign acquirers can no longer assume a deal will clear quietly. With the automatic 15-day suspension for sensitive sectors and Phase II durations stretching to 210 days, transaction timelines have effectively doubled compared to 2023 averages, which stood at 87 days from filing to clearance. The penalty regime also carries real teeth — the previous maximum fine of RMB 500,000 was widely seen as a cost of doing business, whereas the new RMB 50 million cap (or 10% of the acquirer’s prior-year revenue, whichever is higher) demands genuine compliance vigilance.
Key Changes in Filing Thresholds and Timelines
The new guidelines introduce three distinct filing tracks based on the transaction’s characteristics. Track A covers foreign acquisitions in non-sensitive sectors with combined Chinese turnover below RMB 500 million — these can file a simplified notification and typically clear within 30 business days. Track B applies to foreign acquisitions in non-sensitive sectors above that threshold or any deal in a sensitive sector regardless of size — these trigger the standard 30-day Phase I plus up to 210 days in Phase II. Track C is reserved for transactions involving state-owned enterprises (国有企业, guóyǒu qǐyè) or those that could affect national security — these are subject to an inter-agency review involving the Ministry of Commerce (商务部, shāngwù bù) and the National Development and Reform Commission (国家发展和改革委员会, guójiā fāzhǎn hé gǎigé wěiyuánhuì), adding another 60 days on average.
Foreign executives should also note that SAMR now requires a “China Economic Impact Assessment” (中国经济影响评估, zhōngguó jīngjì yǐngxiǎng pínggū) as part of the filing package for Track B and C deals. This document must analyze the transaction’s impact on domestic competition, supply chain resilience, and technology transfer. In practice, this means that acquirers need to prepare substantially more data — including 5 years of market share data, competitor mapping, and projected pricing effects — than was previously required. Anecdotal evidence from law firms in Shanghai suggests that assembling a complete Track B filing now takes an average of 8 weeks, compared to just 3 weeks under the old regime.
Sector-Specific Scrutiny: Where Foreign Acquirers Face the Most Risk
SAMR has been particularly aggressive in semiconductor and AI-related deals. In the first four months of 2025, SAMR blocked or imposed restrictive conditions on 11 foreign acquisitions in these two sectors alone, compared to 3 in all of 2024. The agency’s stated rationale is “protecting indigenous innovation capacity” (保护本土创新能力, bǎohù běntǔ chuàngxīn nénglì), which has led to demands for behavioral remedies such as mandatory licensing of acquired technology to Chinese competitors or commitments to maintain R&D spending within China at or above pre-acquisition levels. For example, in March 2025, a European semiconductor equipment maker’s acquisition of a Chinese sensor startup was approved only after the buyer agreed to spend at least RMB 200 million over three years on a joint R&D center in Shenzhen — a condition that added approximately 15% to the total deal cost.
Foreign acquirers in biopharmaceuticals face a different but equally challenging set of hurdles. SAMR now routinely requests access to clinical trial data and requires undertakings that the acquirer will not withdraw or delay the launch of innovative drugs in the Chinese market post-acquisition. In one high-profile case, a U.S. biotech firm’s acquisition of a Chinese gene therapy developer was held up for 9 months while SAMR negotiated a pricing commitment that caps the annual price increase of any acquired drug at no more than 2.5% above the consumer price index. Such behavioral remedies are becoming standard, and their negotiation can add significant legal and consulting fees — often in the range of RMB 3 million to RMB 8 million per deal — to the transaction’s overall cost.
Practical Compliance Strategies for Foreign Investors
Given the heightened scrutiny, foreign acquirers should adopt a proactive compliance posture from the earliest stages of deal planning. The most effective strategy is to engage SAMR informally before a formal filing — known as a “pre-filing consultation” (预申报, yù shēnbào). These consultations are now strongly encouraged by the agency and typically involve submitting a transaction summary, a preliminary market analysis, and a proposed remedy framework. Data from law firms indicates that deals that undergo pre-filing consultations clear Phase I an average of 22 days faster than those that file without prior engagement, and have a 35% lower likelihood of being pushed into a full Phase II investigation.
Another critical step is to structure the transaction to avoid triggering the most stringent review tracks. For instance, acquiring a minority stake (less than 25%) without board control or veto rights over strategic decisions may qualify for a simplified Track A filing even in a sensitive sector, provided the acquirer does not already hold a similar position in a competing Chinese company. Similarly, conducting the acquisition through a Chinese joint venture partner — where the foreign party holds less than 50% — can sometimes lower the scrutiny level, though this requires careful structuring to avoid de facto control being deemed by SAMR. Foreign acquirers should also budget for a longer and more expensive review process: legal and consulting fees for a Track B filing now average RMB 1.5 million to RMB 4 million, up from approximately RMB 600,000 in 2023.
NEXT STEPS
- Audit your current pipeline for new threshold triggers — Review any pending or near-term acquisition targets in China against the new RMB 1.5 billion global turnover threshold and the 12 sensitive sectors. If a deal qualifies, schedule a pre-filing consultation with SAMR immediately. Read our guide: SAMR Merger Review 2025: Filing Guide for Foreign Acquirers.
- Engage a local antitrust counsel with SAMR experience — Not all law firms have recent experience with the new pre-filing consultation process. Vet firms that handled at least 5 Track B or Track C filings in the past 12 months. See our recommended list: Top 10 Antitrust Law Firms in China for Foreign Acquirers.
- Build a China-specific deal timeline buffer — Add at least 90 days to your expected closing timeline for any acquisition that triggers Track B or C review, and factor in RMB 2 million to RMB 5 million for compliance costs (filing fees, data gathering, legal, and potential remedies). Learn more: M&A in China 2025: Timeline Planning and Cost Projections.
— China Gateway 360 —
Remote China market entry support, built around execution.
